Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice

New treatment strategies are urgently needed for glioblastoma (GBM)—a tumor resistant to standard-of-care treatment with a high risk of recurrence and extremely poor prognosis. Based on their intrinsic tumor tropism, adoptively applied mesenchymal stem cells (MSCs) can be harnessed to deliver the th...

Descripció completa

Dades bibliogràfiques

Autors principals:	Carolin Kitzberger, Khuram Shehzad, Volker Morath, Rebekka Spellerberg, Julius Ranke, Katja Steiger, Roland E. Kälin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, Rainer Glass, Wolfgang A. Weber, Ernst Wagner, Peter J. Nelson, Christine Spitzweg
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2023-09-01
Col·lecció:	Molecular Therapy: Oncolytics
Matèries:	interleukin-6 promoter glioblastoma gene therapy mesenchymal stem cells sodium/iodide symporter NIS
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2372770523000578
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!